These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27598317)

  • 1. Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study.
    Brancaccio D; Neri L; Bellocchio F; Barbieri C; Amato C; Mari F; Canaud B; Stuard S
    Am J Nephrol; 2016; 44(4):258-267. PubMed ID: 27598317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Van Der Meersch H; De Bacquer D; De Vriese AS
    Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
    Winkelmayer WC; Liu J; Setoguchi S; Choudhry NK
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2662-8. PubMed ID: 21959598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation.
    Kai B; Bogorad Y; Nguyen LN; Yang SJ; Chen W; Spencer HT; Shen AY; Lee MS
    Heart Rhythm; 2017 May; 14(5):645-651. PubMed ID: 28185918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.
    Shen JI; Montez-Rath ME; Lenihan CR; Turakhia MP; Chang TI; Winkelmayer WC
    Am J Kidney Dis; 2015 Oct; 66(4):677-88. PubMed ID: 26162653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Nationwide Population-Based Study.
    Yoon CY; Noh J; Jhee JH; Chang TI; Kang EW; Kee YK; Kim H; Park S; Yun HR; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Kim C; Yoo TH
    Stroke; 2017 Sep; 48(9):2472-2479. PubMed ID: 28801476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.
    Dahal K; Kunwar S; Rijal J; Schulman P; Lee J
    Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study.
    Wakasugi M; Kazama JJ; Tokumoto A; Suzuki K; Kageyama S; Ohya K; Miura Y; Kawachi M; Takata T; Nagai M; Ohya M; Kutsuwada K; Okajima H; Ei I; Takahashi S; Narita I
    Clin Exp Nephrol; 2014 Aug; 18(4):662-9. PubMed ID: 24113782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
    Chan PH; Huang D; Yip PS; Hai J; Tse HF; Chan TM; Lip GY; Lo WK; Siu CW
    Europace; 2016 May; 18(5):665-71. PubMed ID: 26504109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies.
    Liu G; Long M; Hu X; Hu CH; Liao XX; Du ZM; Dong YG
    Medicine (Baltimore); 2015 Dec; 94(50):e2233. PubMed ID: 26683937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials.
    Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Valdés M; Vicente V; Roldán V; Lip GYH
    Mayo Clin Proc; 2018 Aug; 93(8):1065-1073. PubMed ID: 29730090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.